期刊文献+

高选择性M受体阻滞剂治疗高龄BPH患者膀胱过度活动症的疗效及安全性 被引量:2

The clinical efficacy and safety of high-selected anticholinergic agents in the treatment of senile patients with overactive bladder and benign prostatic hyperplasia
暂未订购
导出
摘要 目的探讨高选择性M受体阻滞剂索利那新治疗高龄BPH患者膀胱过度活动症(OAB)的疗效及安全性。方法选取2010年7月至2011年5月于我院泌尿外科门诊就诊、年龄≥75岁、确诊为OAB的BPH患者30例,给予索利那新治疗,每日1次,每次5mg,治疗周期3个月。治疗前后以排尿日记、国际前列腺症状评分(IPSS)、膀胱过度活动症状评分(OABSS)、患者感知膀胱症状情况分级量表(PPBC)、生活质量评分(QOL)为主要疗效指标,对疗效及服药安全性进行评价。结果治疗后的24h平均尿急次数、24h平均排尿次数、夜尿次数及每周尿失禁次数均较治疗前好转;IPSS、OABSS、PPBC、QOL评分均低于治疗前,差异具有统计学意义(均P<0.05)。9例患者出现轻度口干、便秘等不良反应,均能耐受,对症治疗后缓解。2例患者出现排尿困难情况,停药1周并加用α受体阻滞剂后缓解。结论高选择性M受体阻滞剂索利那新治疗高龄BPH患者的膀胱过度活动症疗效较好,不良反应轻,是一种相对安全有效的药物治疗方法。 Objective To evaluate the clinical efficacy and safety of high-selected anticholinergic agents(Solifenacin) in the treatment of senile patients with overactive bladder(OAB) and benign prostatic hyperplasia(BPH).Methods 30 senile patients with OAB and BPH were enrolled,whose age were over 75 years.All patients received 5 mg Solifenacin once daily.During 3 months' treatment,all patients recorded urination diary and adverse events.The symptoms of urgency,frequency,nocturia,urine volume,incontinence were evaluated;IPSS,OABSS,PPBC and QOL were analyzed.Results After three months' treatment,all indexes were obviously improved(P0.05).9 cases which reported dry mouth and constipation were improved after therapy.2 cases which reported dysuria were improved after receiving a-blocker treatment.Conclusions High-selected anticholinergic agents(Solifenacin) can be safe and effective in the treatment of OAB patients with BPH.
出处 《现代泌尿外科杂志》 CAS 2013年第2期166-168,共3页 Journal of Modern Urology
关键词 高选择性M受体阻滞剂 膀胱过度活动症 高龄BPH 索利那新 high-selected anticholinergic gents overactive bladder senile patients with OAB and BPH Solifenacin
  • 相关文献

参考文献9

  • 1WARFIELD CA, FAUSETT HJ. Manual of pain management[M].北京:人民卫生出版社,2005:174.
  • 2DEBRUYNE FM, HEESAKKERS JP. Clinical and socioeconom- ic relevance of overactive bladder[J]. Urology, 2004, 63:42-44.
  • 3MILSOM I, ABRAMS P, CARDOZO L, et al. How widespread are the SyMptoMs of an overactive blaadder and how are they managed? A population-based prevalence study[J]. BJU Int, 2010, 87 fl60-766.
  • 4段继宏,杨勇,吴士良,潘柏年,那彦群,薛兆英,郭应禄.北京地区尿失禁发病率调查[J].北京医科大学学报,2000,32(1):74-75. 被引量:239
  • 5MICHEL MC. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha- blockers in the treatment of male voiding dysfunction-how do they work and why do they differ in tolerability[J]. J Pharmacol Sci, 2010, 112:151-157.
  • 6YONO M, YAMAMOTO Y, YOSHIDA M, et al. Effects of doxazosin on blood flow and MRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary traet [J]. Life Sci, 2007, 81: 218-222.
  • 7LAU DH, THOMPSON CS, BELLRINGER JF, et al. Doxazos- in and serotonin (5-HT) receptor (1A, 2A, and 4) antagonists inhibit 5-HT mediated human cavernosal contraction[J]. J An- dro, 2006, 27: 679-685.
  • 8ABRAMS P, ANDERSSON KE. Muscarmic recrptor antagonists for overactive bladder[J]. BJU Int, 2007,100 : 987-1006.
  • 9膀胱过度活动症诊疗的实践与进步——行为、态度、技能、知识项目[J].中华老年医学杂志,2011,30(3):260-262. 被引量:6

二级参考文献3

  • 1[1]Colling J.An update on the AHCPR guideline implementation[J].Nurse Practice Forum,1994,5(3):134-137
  • 2[2]Newman DK.What's new:the AHCPR guideline update on urinary incontinence[J].Ostomy Wound Manage.1996,42(10):46-56
  • 3[3]Brocklehurst JC.Urinary incontinence in the community-analysis of a MORI poll[J].BMJ,1993,306:832-836

共引文献243

同被引文献25

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部